Regulatory Sourcebook eBook
Read the article:
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach
Read the ebook:
Pharmaceutical Technology Regulatory Sourcebook eBook
News|Articles|September 15, 2021
- Pharmaceutical Technology, Regulatory Sourcebook, September 2021
- Volume 2021 eBook
- Issue 3
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach
Author(s)Chris Burgess
A simplified process flow with associated definitions for pharmaceutical sampling and testing is proposed.
Advertisement
For pharma companies and regulators to have meaningful discussion on the results of analyses, they should first agree on the meaning of the terms used. As detailed in Part 1 of this paper, the pharmaceutical industry currently does not have a globally agreed nomenclature for sampling and testing.
Inconsistent sampling and testing processes that may result from this lack of standardized practices can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
In the second part of this paper, the author proposes a simplified overall process flow with associated definitions for pharmaceutical sampling and testing.
About the author
Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 34–40
Citation
When referring to this article, please cite it as C. Burgess, “Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).
Articles in this issue
about 5 years ago
Understanding Combination Product Regulationsabout 5 years ago
Considering Titanium Dioxide Regulatory Changesabout 5 years ago
The Real Danger of Substandard and Counterfeit COVID-19 Vaccinesabout 5 years ago
Changing the Course of Drug Shortagesabout 5 years ago
Industry Organizations Assist Pharma During the Pandemic and Beyondabout 5 years ago
Mapping Out Pharma’s Regulatory Future in EuropeAdvertisement
Related to this article
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5